Results 211 to 220 of about 824,404 (357)

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Advancing Harm Reduction through Data Mapping: The Role of Delaware's Overdose Response Center. [PDF]

Dela J Public Health
Waninger B, Schiavi E.
europepmc   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Correction: Developing a comprehensive inventory to define harm reduction housing. [PDF]

Harm Reduct J
Zaragoza S, Silcox J, Rapisarda S, Summers C, Case P, To C, Chatterjee A, Walley AY, Komaromy M, Green TC.   +9 more
europepmc   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Increasing opportunities for community input in harm reduction program development using iterative engagement. [PDF]

Harm Reduct J
Wagner NM, Carlson JA, Bean M, Wineland A, Blum J, Cardona SA, Covarrubias S, Kempe A, King AC, Huebschmann AG.   +9 more
europepmc   +1 more source

Preventing HIV transmission among Iranian prisoners: Initial support for providing education on the benefits of harm reduction practices [PDF]

, 2008
Babak Eshrati, Rahim Taghizadeh Asl, Colleen Anne Dell, Parviz Afshar, Peggy MargaretE Millson, Mohammad Kamali, John R. Weekes   +6 more
openalex   +1 more source

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

Molecular Oncology, EarlyView.
RAS‐targeted therapies have become a clinical reality. Although promising results in patients have been achieved, there are still challenges ahead such as coping with drug resistance. Here we summarize selected RAS inhibitors targeting either individual KRAS mutant isoforms (KRASG12C, KRASG12D, KRASG12V) or exhibiting a wider inhibitory spectrum ...
Matthias Drosten, Mariano Barbacid
wiley   +1 more source

Psychosocial consequences of xylazine and implications for harm reduction services. [PDF]

Drug Alcohol Depend Rep
Plesons M, Eger WH, Crable EL, Hauschild MH, McElrath CC, Owens C, Forrest DW, Bazzi AR, De Los Santos N, Tookes HE, Bartholomew TS.   +10 more
europepmc   +1 more source

Smoke from traditional commercial, harm reduction and research brand cigarettes impairs oviductal functioning in hamsters (Mesocricetus auratus) in vitro

, 2006
Michael Iv, Vu Long Tran, Ryan Roza, Denise Kwan, Prue Talbot   +4 more
openalex   +1 more source